The company is looking at plans to expand operations to overseas, especially in the neighbouring countries where affordable kidney care options are required, and would have a pilot project established in one of the neighbouring countries by 2015, said Sandeep Gudibanda, co-founder and director, business development, NephroPlus.
"The overseas project would be in a pilot basis, mostly in partnership with a local player, who might be in a related sector," he said, while adding that the details are yet to be finalised. The company today launched its 29th dialysis centre in Chennai, in Vee Care Sundar Hospitals. Plans are to add eight more centres in next 45 days, he added.
Besides, the company would also be looking at tie up with State governments and hospitals, where it can manage the dialysis centres cost effectively for the hospitals, through public private partnership. It is currently managing an ESI facility and a hospital in Andhra Pradesh an is working on managing two more centres in Mandhya Pradesh and Goa for the State governments.
"Many of the hospitals, be it in government or in private sector, are losing their money on dialysis and kidney care as there is no economies of scale of specific expertise. We are open to work with them if they outsource it to us, where we have the economies of scale," he added.
The company is looking at expanding its network to 500 centres in next five years, and to achieve this it has a plan to raise around $30-35 million through a Series C funding after two years.
It has recently completed raising around $10 million in a Series B funding, $3 million from Bessemer Venture Partners and $7 million from IFC, an arm of the World Bank. This is expected to support the company to set up 150 centres in three years. It had a Seried A funding from Bessemer Venture Partners, of an undisclosed amount.
There are around 18 lakh people in the country facing health issues related to kidney failure and require dialysis, while only 1.5 lakh people are currently availing the service. Many of the rest are not aware of the disease while others would skip of default the treatment as it is expensive, with around Rs 30,000 required for dialysis every month.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)